Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Current Leases (2016 - 2025)

Lineage Cell Therapeutics' Current Leases history spans 12 years, with the latest figure at $37000.0 for Q4 2025.

  • For Q4 2025, Current Leases fell 96.63% year-over-year to $37000.0; the TTM value through Dec 2025 reached $37000.0, down 96.63%, while the annual FY2025 figure was $37000.0, 96.63% down from the prior year.
  • Current Leases reached $37000.0 in Q4 2025 per LCTX's latest filing, down from $43000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.1 million in Q4 2024 to a low of $25000.0 in Q3 2022.
  • Average Current Leases over 5 years is $380750.0, with a median of $54500.0 recorded in 2023.
  • Peak YoY movement for Current Leases: tumbled 96.88% in 2022, then soared 2205.56% in 2023.
  • A 5-year view of Current Leases shows it stood at $30000.0 in 2021, then increased by 20.0% to $36000.0 in 2022, then skyrocketed by 2205.56% to $830000.0 in 2023, then soared by 32.17% to $1.1 million in 2024, then plummeted by 96.63% to $37000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Current Leases are $37000.0 (Q4 2025), $43000.0 (Q3 2025), and $998000.0 (Q2 2025).